Novartis: positive results for asthma study
(CercleFinance.com) - On Monday, Novartis announced positive results from the phase III palladium study of the combination of inhaled QMF149 in uncontrolled asthmatic patients.
QMF149 taken once daily showed improvement in the pulmonary function compared to mometaone furoate, reaching the primary endpoint.
Novartis aims to reinvent asthma treatment by inhalation by developing fixed dose combined treatments once daily to help patients better control their asthma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
QMF149 taken once daily showed improvement in the pulmonary function compared to mometaone furoate, reaching the primary endpoint.
Novartis aims to reinvent asthma treatment by inhalation by developing fixed dose combined treatments once daily to help patients better control their asthma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.